INTRODUCTION: Primary open-angle glaucoma (POAG) is an eye disease, which characterized by impairment of retinal neurons resulted in a changes in optic nerve head, damage and death retinal ganglion cells by apoptosis, which lead to loss of vision. Therefore, the scientists were pointed out some resemblance of pathomechanism of neurodegenerative diseases and glaucoma. The number of animal studies have been conducted to examine the role of sirtuins in ocular aging. Upregulation of SIRT1 has been shown to have an important protective effect against various ocular diseases, such as cataract, retinal degeneration, optic neuritis and uveitis. AIM(S): Assessment of the relationship between SIRT1 gene expression level in patients with POAG and the control group. Additionally, analyze the effect of SIRT1 expression level on the progression of POAG depending on clinical parameters. METHOD(S): The study included 34 patients of POAG and 31 control subjects. RNA was extracted from peripheral blood, digested with DNase and converted to cDNA. The SIRT1 expression levels were measured by QPCR method. The non‑parametric Mann‑Whitney U test was applied to determine the levels of mRNA expression in blood of POAG patients and healthy subjects. The non-parametrical statistical tests (ANOVA with post hoc Tukey’s HSD test) were applied to compare level of mRNA expression with clinical parameters of POAG patients. RESULTS: The results shown no statistically significant differences between SIRT1 mRNA levels of POAG patients and controls (p>0.05). However, there was significant association of the SIRT1 expression level with progression of POAG based on RA value (Rim Area), p=0.012. We observed increase of SIRT1 expression level with the early stage of glaucoma, which confirms the protective role of sirtuin in the development of glaucoma. CONCLUSIONS: In conclusion, our study showed a statistically significant association of SIRT1 genes with progression of POAG in a Polish population. FINANCIAL SUPPORT: This work was supported by Umed in Lodz Grants no 500/5-108-05/500-41.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.